CICERO-19 (COVID-19) [COVID-19]
Research type
Research Study
Full title
Cambridge Investigation of Cardiac Complications of Severe COVID-19 (CICERO-19) *STUDY NEVER COMMENCED*
IRAS ID
283884
Contact name
Joseph Cheriyan
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust
Duration of Study in the UK
0 years, 11 months, 29 days
Research summary
*STUDY NEVER COMMENCED* SARS-CoV-2 is the viral pathogen responsible for the novel COVID-19 disease. The effects of COVID-19 on respiratory system is known, whereas, the alterations in cardiac (heart) function during and following SARS-CoV-2 infection is not well understood. \n\nThis observational study is aimed at investigating cardiovascular complications of COVID-19, using laboratory, echo and magnetic resonance imaging (MRI) to assess myocardial function and injury, and ECG monitoring to identify the frequency and severity of dysrhythmias (abnormality in rhythm of heart). Specialised blood tests for studying the immune system will be performed. \n\nTests to study endothelium – the lining of the blood vessels in the arteries and veins, which has been shown to be affected by coronavirus infection, will also be performed. Cardiovascular disease associated with COVID-19 may be underestimated, contribute to the high death rates, hence its recognition will allow for prevention, early diagnosis and appropriate treatment.\n
REC name
London - Camberwell St Giles Research Ethics Committee
REC reference
20/HRA/3130
Date of REC Opinion
10 Aug 2020
REC opinion
Further Information Favourable Opinion